

Evonik receives Asia–Pacific Bioprocessing Excellence Award second year in a row

- Evonik selected for high–quality Cell Culture Solutions
- Award celebrates innovation in biopharmaceutical technologies
- Portfolio expansion and strengthening of application and formulation competence with biosolutions

Essen, Germany. Evonik has been awarded an Asia–Pacific Bioprocessing Excellence Award (ABEA) for the second year running. The company received the award for its Cell Culture Solutions portfolio in the category Best New Bioprocessing Supplier Award: Upstream Processing. Cell culture is a key growth area for Evonik’s Health Care business.

As part of the company’s life sciences division, Nutrition & Care, the Cell Culture Solutions offered by Evonik are a cornerstone to its expanding portfolio of biosolutions. Customers benefit from a tailored offering of ingredients, as well as application and formulation expertise as a system solution. Nutrition & Care aims to increase its share of system solutions to 70 percent by 2032.

“It is a great honor to be recognized by the Asia–Pacific biopharma community for the second year in a row. We look forward to many more fruitful collaborations with companies in the region and look forward to exceeding their cell culture media and bioprocessing needs,” said Shirley Qi, President Southeast Asia, Australia & New Zealand/head of Nutrition & Care Asia Pacific at Evonik.

The annual Asia–Pacific Biopharma Excellence Awards (ABEA) are organized by the global biopharmaceutical B2B and marketing intelligence company IMAPAC. The awards applaud exceptional leaders, organizations and technologies that drive innovation and best practices in manufacturing in the region.

“Winning this award is a testament to the efforts of our team to serve the biopharma community. Our success further encourages us to develop more innovative solutions to solve bioprocessing challenges with our cell culture solutions portfolio,” said Spandan

21 March 2024

Main press contact

Cheerio Chan
Regional Communications –
Southeast Asia, Australia
& New Zealand
Evonik
Phone +65 6809 6839
cheerio.chan@evonik.com

Alternative press contact

Dr. Jürgen Krauter
Head of Market Communications Evonik
Phone +49 6181 59–6847
juergen.krauter@evonik.com

Evonik Industries AG
Rellinghauser Straße 1–11
45128 Essen
Germany
Phone +49 201 177–01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Maike Schuh, Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

Mishra, Associate Director Business Development – Biopharma Solutions at Evonik Health Care for Asia Pacific.

Evonik’s extensive Cell Culture Solutions portfolio combines development expertise and manufacturing capabilities to provide highly defined and pure cell culture ingredients for use in a wide range of applications, from biopharmaceutical R&D and manufacturing to medicinal purposes. Evonik’s solutions include the cQrex® portfolio of peptides that address specific amino acid limitations to improve stability and solubility, enabling optimal productivity and enhancing performance in biopharmaceutical cell culture media. Other specialty ingredients like carbohydrates, and the plant-derived cholesterol PhytoChol® Biopharma are also part of Evonik’s offering.

The Health Care business line at Evonik is a global innovation hub to the world’s leading pharma and biotech companies. By leveraging six decades of industry leadership, the company provides the biopharma market with high-quality cell culture solutions including amino acids, peptides, plant-based lipids and other non-animal-derived performance boosters.

The ABEA awards ceremony was held in conjunction with the 11th Biologics Manufacturing Asia 2024, which took place in Singapore on March 20.

Further Information

Find out more about Evonik’s Cell Culture Solutions
<https://healthcare.evonik.com/en/biopharma/cell-culture>

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and

household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.